TCGA-63-A5MM-01A-11R-A26W-07
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 69
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- TNFA_SIGNALING_VIA_NFKB+0.610
- INTERFERON_GAMMA_RESPONSE+0.600
- ANGIOGENESIS+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.570
- IL6_JAK_STAT3_SIGNALING+0.520
- ALLOGRAFT_REJECTION+0.510
- INFLAMMATORY_RESPONSE+0.500
- P53_PATHWAY+0.470
- COMPLEMENT+0.380
Top 10 suppressed
- PEROXISOME-0.350
- BILE_ACID_METABOLISM-0.310
- HEME_METABOLISM-0.310
- SPERMATOGENESIS-0.240
- FATTY_ACID_METABOLISM-0.210
- CHOLESTEROL_HOMEOSTASIS-0.200
- PROTEIN_SECRETION-0.130
- KRAS_SIGNALING_DN-0.090
- ADIPOGENESIS-0.080
- MITOTIC_SPINDLE-0.060
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_3J85TTZM | MPNST | — | 0.892 |
| 2 | TCGA-FD-A62N-01A-11R-A30C-07 | — | — | 0.887 |
| 3 | TCGA-63-A5MT-01A-21R-A26W-07 | — | cohortSQ1 | 0.884 |
| 4 | SRR817658 | GTEX | — | 0.879 |
| 5 | R317 | — | — | 0.877 |
| 6 | SRR819346 | GTEX | — | 0.873 |
| 7 | R409 | — | — | 0.873 |
| 8 | TCGA-66-2744-01A-01R-0980-07 | — | cohortA1 | 0.871 |
| 9 | TCGA-50-6595-01A-12R-1858-07 | — | cohortA1 | 0.865 |
| 10 | F547C7BB-DBF1-4805-A0EA-D8BC36606032 | — | — | 0.862 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 36 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.610 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.580 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.570 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.520 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.510 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| P53_PATHWAY | 0.470 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| APOPTOSIS | 0.370 | Idelalisib | — uncovered |
| HYPOXIA | 0.370 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.360 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.350 | Inavolisib | — uncovered |
| COAGULATION | 0.330 | Binimetinib | — uncovered |
| DNA_REPAIR | 0.310 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.310 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.290 | Temsirolimus | — uncovered |
| E2F_TARGETS | 0.270 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.260 | Idelalisib | — uncovered |